Form 4: Fortress Biotech Acquires Shares in Checkpoint Therapeutics as Equity Fee

Fortress Biotech, a 10% owner of Checkpoint Therapeutics, acquired 193,905 shares of common stock as an equity fee related to a financing consummated by Checkpoint.

Summary

• On March 20, 2024, Fortress Biotech acquired 193,905 shares of Checkpoint Therapeutics' common stock.
• The acquisition was an equity fee granted by Checkpoint Therapeutics to Fortress Biotech, representing 2.5% of the gross amount of a debt or equity financing recently completed by Checkpoint.
• Following the transaction, Fortress Biotech directly owns 2,096,278 shares of Checkpoint Therapeutics.
• Samuel Berry, General Counsel and Authorized Agent, signed the Form 4 on behalf of Fortress Biotech on March 22, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a transaction related to a pre-existing agreement. The acquisition of shares by Fortress Biotech could be seen as a positive sign, but it's primarily a contractual obligation.

Positives

• Fortress Biotech's increased stake in Checkpoint Therapeutics could signal confidence in the company's future prospects.

Risks

• The equity fee arrangement could dilute existing shareholders' ownership if Checkpoint Therapeutics continues to use this method for financing.

Industry Context

Equity fee arrangements are sometimes used in the biotech industry to compensate financial partners for their role in securing funding. This arrangement aligns the interests of the financing partner with the success of the company.

Related Party Transactions

• The grant of shares to Fortress Biotech as an equity fee constitutes a related party transaction, as Fortress Biotech is a 10% owner of Checkpoint Therapeutics.

Stakeholder Impact

• Existing shareholders may experience dilution due to the issuance of new shares to Fortress Biotech.

Key Dates